First phase of pharmacare must not ‘create new gaps’ in existing coverage, say lobbyists
Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.
Trudeau’s pharmacare plan would likely reduce drug coverage for millions of Canadians
The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.
Trudeau government not being honest about true costs of national pharmacare
The government will likely need to borrow to finance any new spending and add more debt, which will result in higher taxes in the future. And yet, pharmacare is being presented to Canadians as if there’s no direct cost to them.
Florida importation program won’t cause drug shortages in Canada: state secretary
Florida’s plan is designed to relieve pressure on an already overburdened government health-care system, and will bring tens, if not hundreds, of millions of dollars in new business to Canada.
FDA approval may spell trouble for Canadian patients
The FDA’s Florida decision might wind up limiting Canadians’ access to pharmaceutical medicines as long as Canadian drug prices remain well below prices in the United States.
Global trade disruptions and election fever contribute to ‘unpredictable’ 2024 for advocacy, say lobbyists
Pharmacare and Bill C-234, an act to amend the Greenhouse Gas Pollution Pricing Act, are likely to be top issues for government relations this year.
A prescription for equity: ensuring young Canadians’ health through National Pharmacare
A public pharmacare program that provides coverage for all Canadians, regardless of age, occupation, or income, would alleviate financial burdens and allow people to choose jobs based on the work and wages, rather than the cost of the company drug plan.
Questions count when it comes to finding out how Canadians feel about pharmacare
If we want politicians to know what’s important, we need to make sure that they hear answers to questions that get at the heart of the pharmacare issue.
Government hostility to biopharmaceutical industry reduces access to innovative drugs
Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.
Multi-payer pharmacare will fail Canadians
Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.
